Direct-acting antiviral therapy can lower risk of ESKD in patients with HCV
When treated with direct-acting antiviral therapy, sufferers with chronic hepatitis C virus contamination decreased the chance for end-stage kidney disease and the composite of ESKD or death, according to a speaker at ASN Kidney Week.
“The rationale for our study is that hepatitis C is known to be associated with increased incidences of chronic kidney disease and ESKD and progressive loss of kidney function in general,” Fridtjof Thomas, Ph.D., professor at the University of Tennessee Health Science Center, said. “Therefore, the query is whether or not direct-appearing antiviral (DAA) therapy in hepatitis C patients reduces subsequent CKD and ESKD.”After figuring out a national cohort of U.S. veterans with HCV infection via viral load testing, researchers extracted statistics on any DAA therapy with the use of pharmacy dispensation data. Researchers then investigated the correlation of DAA remedy (in comparison with no DAA therapy) with the incidence of ESKD and the composite of ESKD or loss of life the use of Cox fashions adjusted for demographic characteristics, socioeconomic characteristics, comorbid conditions, and baseline kidney function and proteinuria. In total, 114,358 patients had HCV infection (imply age at HCV diagnosis, fifty-five years; imply eGFR, ninety two mL/min/1.seventy three m2; 97% had been men; 38% had been African American; 8% had proteinuria) and 51% of them acquired a course of DAA remedy among 2014 and 2018. During a mean follow-up of 11.5 years, there had been 497 ESKD events and 26,684 composite occasions.
“The [DAA] therapy is associated with a lower danger of end-stage renal disease and the composite outcome as well. This conclusion is based on DAA time-dependent covariate and the model that correctly limits exposure time for DAA therapy to the time after the first initiation,” Thomas said.
Photo by Karolina Grabowska from Pexels
